Index
Technical Report Documentation Page
Introduction
Cannabis/Marijuana
Carisoprodol (and Meprobamate)
Cocaine
Dextromethorphan
Diazepam
Diphenhydramine
Gamma-Hydroxybutyrate (GHB, GBL,
and 1,4-BD)
Ketamine
Lysergic acid diethylamide (LSD)
Methadone
Methamphetamine (and Amphetamine)
Methylenedioxymethamphetamine
(MDMA, Ecstasy)
Morphine (and Heroin)
Phencyclidine (PCP)
Toluene
Zolpidem (and Zaleplon, Zopiclone)
Biographical Sketches of Lead
Authors and Main Contributors |
|
Morphine and heroin are white, crystalline powders. Illicit heroin
may vary in color from white to dark brown due to impurities, or may
appear as a black tar-like material.
Synonyms: Morphine: Astramorph®, Duramorph®, Infumorph®, Kadian®, Morphine
Sulfate®, MSIR®, MS-Contin®, Oramorph SR®, Roxanol®. Heroin:
diacetylmorphine, diamorphine; Mexican brown or Mexican black tar heroin;
bags, blue-steel, China white, H, horse, junk, no-name, silk, skag,
smack. Scramble (cut heroin), bone (uncut heroin for smoking), chippers
(occasional users).
Source: Morphine is a naturally occurring
substance extracted from the seedpod of the poppy plant, Papavar
somniferum. The milky resin that seeps from incisions made in the
unripe seedpod is dried and powdered to make opium, which contains a
number of alkaloids including morphine. Morphine concentration in opium
can range from 4-21%. An alternate method of harvesting morphine is
by the industrial poppy straw process of extracting alkaloids from the
mature dried plant, which produces a fine brownish powder. Morphine
is a schedule II controlled substance and is available in a variety
of prescription forms: injectables (0.5-25 mg/mL strength); oral solutions
(2-20 mg/mL); immediate and controlled release tablets and capsules
(15-200 mg); and suppositories (5-30 mg). Heroin is a schedule I controlled
substance and is produced from morphine by acetylation at the 3 and
6 positions. The majority of heroin sold in the U. S. originates from
Southeast Asia, South America (Columbia) and Mexico. Low purity Mexican
black tar heroin is most common on the West coast, while high purity
Columbian heroin dominates in the East and most mid-western states.
Drug Class: Narcotic analgesic.
Medical and Recreational Uses: Morphine
is used medicinally for the relief of moderate to severe pain in both
acute and chronic management. It can also be used to sedate a patient
pre-operatively and to facilitate the induction of anesthesia. Heroin
has no currently accepted medical uses in the U.S., however, it is an
analgesic and antitussive.
Potency, Purity and Dose: The dosage of
morphine is patient-dependent. A usual adult oral dose of morphine is
60-120 mg daily in divided doses, or up to 400 mg daily in opioid tolerant
patients. Recreationally, daily heroin doses of 5-1500 mg have been
reported, with an average daily dose of 300-500 mg. Addicts may inject
heroin 2-4 times per day. Depending on the demographic region, the street
purity of heroin can range from 11-72% (average U.S. purity is ~38%).
Heroin may be cut with inert or toxic adulterants such as sugars, starch,
powdered milk, quinine, and ketamine. Heroin is often mixed with methamphetamine
or cocaine (“speedball”) and injected; or co-administered
with alprazolam, MDMA (Ecstasy), crack cocaine, or diphenhydramine.
Route of Administration: Morphine:
oral, intramuscular, intravenous, rectal, epidural, and intrathecal
administration. Morphine tablets may be crushed and injected, while
opium can be smoked. Heroin: smoked, snorted, intravenous
(“mainlining”), and subcutaneous (“skin popping”)
administration. Black tar heroin is typically dissolved, diluted and
injected, while higher purity heroin is often snorted or smoked.
Pharmacodynamics: Morphine produces its
major effects on the CNS primarily through m-receptors, and also at
k- and d-receptors. m 1-receptors are involved in pain modulation, analgesia,
respiratory depression, miosis, euphoria, and decreased gastrointestinal
activity; m 2-receptors are involved in respiratory depression, drowsiness,
nausea, and mental clouding; k-receptors are involved in analgesia,
diuresis, sedation, dysphoria, mild respiratory depression, and miosis;
and d-receptors are involved in analgesia, dysphoria, delusions, and
hallucinations. Heroin has little affinity for opiate receptors and
most of its pharmacology resides in its metabolism to active metabolites,
namely 6-acetylmorphine, morphine, and morphine-6-glucuronide.
Pharmacokinetics: The oral bioavailability
of morphine is 20-40%, and 35% is bound in plasma. Morphine has a short
half-life of 1.5 - 7 hours and is primarily glucuroconjugated at positions
3 and 6, to morphine-3-glucuronide (M3G) and morphine-6-glucuronide
(M6G), respectively. A small amount (5%) is demethylated to normorphine.
M6G is an active metabolite with a higher potency than morphine, and
can accumulate following chronic administration or in renally impaired
individuals. The half-life of M6G is 4 +/- 1.5 hours. Close to 90% of
a single morphine dose is eliminated in the 72 hours urine, with 75%
present as M3G and less than 10% as unchanged morphine. Heroin has an
extremely rapid half-life of 2-6 minutes, and is metabolized to
6-acetylmorphine and morphine. The half-life of 6-acetylmorphine is
6-25 minutes. Both heroin and 6-acetylmorphine are more lipid soluble
than morphine and enter the brain more readily.
Molecular Interactions / Receptor Chemistry: The
uridine 5’-diphosphate-glucuronosyltransferase (UGT) 2B7 isoform
is primarily involved in the metabolism of morphine. Potential inhibitors
of this UGT isoform could decrease the rate of morphine elimination
if administered concurrently, while potential inducers
could increase the rate of elimination.
Blood to Plasma Concentration Ratio: Morphine
1.02; M6G 0.57; M3G 0.59
Interpretation of Blood Concentrations: Tolerance
makes interpretation of blood or plasma morphine concentrations extremely
difficult. Peak plasma morphine concentrations occur within an hour
of oral administration, and within 5 minutes following intravenous injection.
Average plasma concentrations of 0.065 mg/L are necessary for adequate
therapeutic analgesia in ambulatory patients. Anesthetic concentrations
can reach beyond 2 mg/L in surgical patients. Following oral doses of
10-80 mg, corresponding peak morphine concentrations in serum were 0.05-0.26
mg/L. Following an intravenous dose of 8.75g/70 kg, a peak serum concentration
of 0.44 mg/L was reached. In 10 intravenous drug fatalities, where morphine
was the only drug detected, postmortem whole blood morphine concentrations
averaged 0.70 mg/L (range 0.20-2.3 mg/L). Following a single 12 mg intravenous
mg dose of heroin, a peak heroin concentration of 0.141 mg/L was obtained
at 2 minutes, while the 6-acetylmorphine and morphine concentrations
were 0.151 and 0.044, respectively. A single 5 mg intravenous dose of
heroin produced a peak plasma morphine concentration of 0.035 mg/L at
25 minutes, while intravenous doses of 150-200 mg have produced plasma
morphine concentrations of up to 0.3 mg/L. Intranasal administration
of 12 mg heroin in 6 subjects produced average peak concentrations of
0.016 mg/L heroin in plasma within 5 minutes; 0.014 mg/L of 6-acetylmorphine
at 0.08-0.17 hours; and 0.019 mg/L of morphine at 0.08-1.5 hours.
Interpretation of Urine Test Results: Positive
morphine urine results generally indicate use within the last two to
three days, or longer after prolonged use. Detection of 6-acetylmorphine
in the urine is indicative of heroin use. High concentrations may indicate
chronic use of the drug. It is important to hydrolyze urine specimens
to assess a urine morphine concentration.
Effects: Depends heavily on the dose of morphine
or heroin, the route of administration, and previous exposure. Following
an intravenous dose of heroin, the user generally feels an intense surge
of euphoria (“rush”) accompanied by a warm flushing of the
skin, dry mouth, and heavy extremities. The user then alternates between
a wakeful and drowsy state (“on the nod”).
Psychological: Euphoria, feeling of well-being, relaxation,
drowsiness, sedation, lethargy, disconnectedness, self-absorption, mental
clouding, and delirium.
Physiological: Analgesia, depressed heart rate, respiratory
depression, CNS depression, nausea and vomiting, reduced gastrointestinal
motility, constipation, flushing of face and neck due to dilatation
of subcutaneous blood vessels, cramping, sweating, pupils fixed and
constricted, diminished reflexes, and depressed consciousness.
Side Effect Profile: Drowsiness, inability
to concentrate, apathy, lessened physical activity, constipation, urinary
retention, nausea, vomiting, tremors, itching, bradycardia, severe respiratory
depression, and pulmonary complications such as pneumonia. Medical complications
among abusers arise primarily from adulterants found in street drugs
and in non-sterile injecting practices, and may include skin, lung and
brain abscesses, collapsed veins, endocarditis, hepatitis and HIV/AIDS.
Overdose can include slow, shallow breathing, clammy skin, convulsions,
extreme somnolence, severe respiratory depression, apnea, circulatory
collapse, cardiac arrest, coma, and death.
Duration of Effects: Depending on the morphine
dose and the route of administration, onset of effects is within 15-60
minutes and effects may last 4-6 hours. The duration of analgesia increases
progressively with age although the degree of analgesia remains unchanged.
Following heroin use, the intense euphoria lasts from 45 seconds to
several minutes, peak effects last 1-2 hours, and the overall effects
wear off in 3-5 hours, depending on dose.
Tolerance, Dependence and Withdrawal Effects: Both
morphine and heroin have high physical and psychological dependence.
With regular use, tolerance develops early to the duration and intensity
of euphoria and analgesia. Withdrawal symptoms may occur if use is abruptly
stopped or reduced. Withdrawal can begin within 6-12 hours after the
last dose and may last 5-10 days. Early symptoms include watery eyes,
runny nose, yawning and sweating. Major withdrawal symptoms peak between
48-72 hours after the last dose and include drug craving, restlessness,
irritability, dysphoria, loss of appetite, tremors, severe sneezing,
diarrhea, nausea and vomiting, elevated heart rate and blood pressure,
chills alternating with flushing and excessive sweating, goose-flesh,
abdominal cramps, body aches, muscle and bone pain, muscle spasms, insomnia,
and severe depression.
Drug Interactions: Alcohol increases the
CNS effects of morphine such as sedation, drowsiness, and decreased
motor skills. There is a higher risk of respiratory depression, hypotension
and profound sedation or coma with concurrent treatment or use of other
CNS depressant drugs such as barbiturates, benzodiazepines, hypnotics,
tricyclic antidepressants, general anesthetics, MAO inhibitors, and
antihistamines. Morphine may enhance the neuromuscular blocking action
of skeletal muscle relaxants and produce an increased degree of respiratory
depression. Small doses of amphetamine substantially increase the analgesia
and euphoriant effects of morphine and may decrease its sedative effects.
Antidepressants may enhance morphine’s analgesia. Partial agonists
such as buprenorphine, nalbuphine, butorphanol, and pentazocine will
precipitate morphine withdrawal.
Performance Effects: Laboratory studies
have shown that morphine may cause sedation and significant psychomotor
impairment for up to 4 hours following a single dose in normal individuals.
Early effects may include slowed reaction time, depressed consciousness,
sleepiness, and poor performance on divided attention and psychomotor
tasks. Late effects may include inattentiveness, slowed reaction time,
greater error rate in tests, poor concentration, distractibility, fatigue,
and poor performance in psychomotor tests. Subjective feelings of sedation,
sluggishness, fatigue, intoxication, and body sway have also been reported.
Significant tolerance may develop making effects less pronounced in
long-term users for the same dose. In a laboratory setting, heroin produced
subjective feelings of sedation for up to 5-6 hours and slowed reaction
times up to 4 hours, in former narcotic addicts. Euphoria and elation
could also play a role on perception of risks and alteration of behaviors.
Effects on Driving: The drug manufacturer
states that morphine may impair the mental and/or physical abilities
needed to perform potentially hazardous activities such as driving a
car, and patients must be cautioned accordingly. Driving ability in
cancer patients receiving long-term morphine analgesia (mean 209 mg
daily) was considered not to be impaired by the sedative effects of
morphine to an extent that accidents might occur. There were no significant
differences between the morphine treated cancer patients and a control
group in vigilance, concentration, motor reactions, or divided attention.
A small but significant slowing of reaction time was observed at 3 hours.
In several driving under the influence case reports, where the subjects
tested positive for morphine and/or 6-acetylmorphine, observations included
slow driving, weaving, poor vehicle control, poor coordination, slow
response to stimuli, delayed reactions, difficultly in following instructions,
and falling asleep at the wheel.
DEC Category: Narcotic Analgesic.
DEC Profile: Horizontal gaze nystagmus not
present; vertical gaze nystagmus not present; lack of convergence not
present; pupil size constricted; little or no reaction to light; pulse
rate down; blood pressure down; body temperature down. Other characteristic
indicators may include presence of fresh injection marks, track marks,
flaccid muscle tone, droopy eyelids, drowsiness or “on-the-nod”,
and low raspy slow speech.
Panel’s Assessment of Driving Risks: Classification
of risk depends on tolerance, dose, time of exposure, acute or chronic
use, presence or absence of underlying pain, physiological status of
individual, and the presence of other drugs. Moderately to severely
impairing in non-tolerant individuals. Mild to moderately impairing
if morphine is used as medication on a regular basis for chronic pain.
Severely impairing in acute situations if used orally, or as an intravenous
medication, or if either drug is taken illicitly.
References and Recommended Reading:
Baselt RC. Drug effects on psychomotor performance. Biomedical
Publications, Foster City, CA; pp 186-8, pp 277-81; 2001.
Clemons M,
Regnard C, Appleton T. Alertness, cognition and morphine in patients
with advanced cancer. Cancer Treat Rev 1996;22(6):451-68. Community Epidemiology Working Group, National Institute on Drug
Abuse. Epidemiological trends in drug abuse; Proceedings of the
Community Epidemiology Working Group, Vol 1;June 2000.
Cone E J, Holicky BA, Grant TM, Darwin WD, Goldberger BA. Pharmacokinetics
and pharmacodynamics of intranasal "snorted" heroin. J
Anal Toxic 1993;17(6):327-37.
Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. Eur
Respir J 2000;15(3):590-5.
Gjerde H, Morland J. A case of high opiate tolerance: implications
for drug analyses and interpretations. Addict Behav 1991;16(6):507-16.
Hanks GW, O'Neill WM, Simpson P, Wesnes K. The cognitive and psychomotor
effects of opioid analgesics. II. A randomized controlled trial of single
doses of morphine, lorazepam and placebo in healthy subjects. Eur
J Clin Pharmacol 1995;48(6):455-60.
Kerr B, Hill H, Coda B, Calogero M, Chapman CR, Hunt E, Buffington
V, Mackie A. Concentration-related effects of morphine on cognition
and motor control in human subjects. Neuropsychopharmacology 1991;5(3):157-66.
Mason MF. Drug impairment reviews: opiates, minor tranquilizers. NIDA
Research Monograph 1977;11:44-60.
Physicians’ Desk ReferenceWhat is MMUCC
MMUCC Committee
MMUCC Documents
What is MMUCC?
The Model Minimum Uniform Crash Criteria (MMUCC) is a minimum set of crash data elements with standardized definitions that are relevant to injury control, highway and traffic safety. Not all of the MMUCC data elements need to be collected by police at the scene. Instead, some can be created from other data elements, such as the Vehicle Identification Number, to identify a specific vehicle characteristic. Or they can be obtained after linkage to other traffic records, such as injury or roadway inventory data to describe injury outcome or a specific roadway characteristic.
FOR MORE INFORMATION ON THE MMUCC, PLEASE CLICK ON
www-nrd.nhtsa.dot.gov/departments/nrd-30/ncsa/MMUCC.html
Top of Page
MMUCC Committee
Acknowledgements
The development of the Guideline for Minimum Uniform Crash Criteria (MMUCC) is being sponsored by the National Association of Governors' Highway Safety Representatives, the National Highway Traffic Safety Administration, and the Federal Highway Administration. Numerous state and local agencies and organizations have contributed staff to its development. The participation of the following individuals is recognized:
Frank Carlile
David Dickens
Doug Donscheski
Scott Falb
Rosa Gill
Dick Harmon
Don Hillis
David Kleppe
David Lawrence
Lance Mathess
Creighton Miller
David Mosley
Phil Salzberg
Manu Shah
James Templeton
Robert Thompson
John Watson
Ralph Craft
Dennis Flemons
Carl Hayden
Janet Johnson
Sandy Johnson
Janet Kumer
Tina Morgan
Ed Milton
Jack Oates
Barbara Rhea
Jackie Schraf
David Sleet
Carol Tan Esse
Dennis Utter
David Bozak
Noel Bufe
Charles Compton
Barbara Harsha
Roy Lucke
Gary March
Matt Snyder
Richard Pain
Charles Peltier
Patricia Waller Florida Department of Transportation
Charleston West Virginia Police
Nebraska State Patrol
Iowa Department of Transportation
North Carolina State Division of Motor Vehicles
Iowa Bureau of Emergency Medical Services
Missouri Department of Transportation
North Dakota State Highway Patrol
Louisiana Office of Public Health
Ohio State Patrol
South Dakota Office of Accident Records
Virginia Department of Motor Vehicles
Washington Traffic Safety Commission
Maryland State Highway Administration
Texas Department of Public Safety
Iowa Governor's Traffic Safety Bureau
New York State Department of Transportation
Federal Highway Administration
National Highway Traffic Safety Administration
Federal Highway Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
Federal Highway Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Center for Injury Prevention and Control
Federal Highway Administration
National Highway Traffic Safety Administration
InfoGroup, Inc.
Northwestern University Traffic Institute
University of Michigan Transportation Research Institute
National Association of Governors' Highway Safety Reps
Northwestern University Traffic Institute
March & Associates
International Association of Chiefs of Police
Transportation Research Board
International Association of Chiefs of Police
University of Michigan Transportation Research Institute
Top of Page
MMUCC Documents
To visit the MMUCC Homepage, please click on the following link:
Model Minimum Uniform Crash Criteria--Improving Crash Data for Safer Roadways
The following links will take you to several documents related to the MMUCC effort.
Download a PDF of the Final Guidelines (522KB) for Minimum Standardized Crash Data Reporting
,
Medical Economics Company,
Montvale, NJ, 2002.
Pickworth WB, Rohrer MS, Fant RV. Effects of abused drugs on psychomotor
performance. Exp Clin Psychopharmacol 1997;5(3):235-41.
Sjogren P. Psychomotor and cognitive functioning in cancer patients. Acta
Anaesthesiologica Scandinavica 1997;41(1 Pt 2):159-61.
Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. Driving ability
in cancer patients receiving long-term morphine analgesia. Lancet 1995;346(8976):667-70.
Wagner B, O'Hara D. Pharmacokinetics and pharmacodynamics of sedatives
and analgesics in the treatment of agitated critically ill patients. Clin
Pharmacokin 1997;33(6):426-53.
Walker D, Zacny J. Subjective, psychomotor, and analgesic effects
of oral codeine and morphine in healthy volunteers. Psychopharmacology 1998;140(2):191-201.
Walker D, Zacny J. Subjective, psychomotor, and physiological effects
of cumulative doses of opioid mu agonists in healthy volunteers. J
Pharmacol Exp Ther 1999;289(3):1454-64.
Zacny JP, Conley K, Marks S. Comparing the subjective, psychomotor
and physiological effects of intravenous nalbuphine and morphine in
healthy volunteers. J Pharmacol Exp Ther 1997;280(3):1159-69.
Zacny JP, Hill J, Black ML, Sadeghi P. Comparing the subjective, psychomotor
and physiological effects of intravenous pentazocine and morphine in
normal volunteers. J Pharmacol Exp Therapeutics 1998;286(3):1197-207.
Zacny JP, Lichtor JL, Thapar P, Coalson DW, Flemming D, Thompson WK.
Comparing the subjective, psychomotor and physiological effects of intravenous
butorphanol and morphine in healthy volunteers. J Pharmacol Exp
Ther 1994;270(2):579-88.
Zacny JP, Lichtor JL, Flemming D, Coalson DW, Thompson WK. A dose-response
analysis of the subjective, psychomotor and physiological effects of
intravenous morphine in healthy volunteers. J Pharmacol Exp Ther 1994;268(1):1-9.
|